MLchartDataset catalogue

Dexverapamil

Term · Oncology and biomedicine · MLC-T-ONC-013018

The R-enantiomer of the calcium channel blocker verapamil. Dexverapamil competitively inhibits the multidrug resistance efflux pump P-glycoprotein (MDR-1), thereby potentially increasing the effectiveness of a wide range of antineoplastic drugs which are inactivated by MDR-1 mechanisms. This agent exhibits decreased calcium antagonistic activity and toxicity compared to racemic verapamil.

Table 1. Record
IdentifierMLC-T-ONC-013018
FieldOncology and biomedicine
SynonymsR verapamil; R-verapamil; R-Verapamil Hydrochloride
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-013018",
  "term": "Dexverapamil",
  "field": "Oncology and biomedicine",
  "definition": "The R-enantiomer of the calcium channel blocker verapamil. Dexverapamil competitively inhibits the multidrug resistance efflux pump P-glycoprotein (MDR-1), thereby potentially increasing the effectiveness of a wide range of antineoplastic drugs which are inactivated by MDR-1 mechanisms. This agent exhibits decreased calcium antagonistic activity and toxicity compared to racemic verapamil.",
  "synonyms": [
    "R verapamil",
    "R-verapamil",
    "R-Verapamil Hydrochloride"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/dexverapamil/"
}

Record 5,905 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.